Narrow search
Showing 1 - 10 of 408
Cover Image
Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007
Conti, Rena M.; Berndt, Ernst R. - National Bureau of Economic Research (NBER) - 2014
We examine the impact of loss of U.S. patent exclusivity (LOE) on the prices and utilization of specialty drugs between 2001 and 2007. We limit our empirical cohort to drugs commonly used to treat cancer and base our analyses on nationally representative data from IMS Health. We begin by...
Persistent link: https://www.econbiz.de/10010950850
Cover Image
Does the Profit Motive Make Jack Nimble? Ownership Form and the Evolution of the U.S. Hospital Industry
Gaynor, Martin; Klepper, Steven; Vogt, William; … - National Bureau of Economic Research (NBER) - 2005
entry and exit behavior. We develop theoretical predictions based on the model of Lakdawalla and Philipson, in which for … be quicker to enter and exit than not-for-profits in response to changing market conditions. We test this hypothesis … using data for all U.S. hospitals from 1984 through 2000. Examining annual and regional entry and exit rates, for …
Persistent link: https://www.econbiz.de/10005085246
Cover Image
The Effect of FDA Advisories on Branded Pharmaceutical Firms' Valuations and Promotion Efforts
Conti, Rena M.; Huskamp, Haiden A.; Berndt, Ernst R. - National Bureau of Economic Research (NBER) - 2011
The US Food and Drug Administration (FDA) expends considerable efforts in regulating medications approved for use. Yet the impact of medication labeling changes on brand pharmaceutical products, and whether and what firms do to respond to increased information regarding the safety and efficacy...
Persistent link: https://www.econbiz.de/10009325511
Cover Image
Impact of Mortality-Based Performance Measures on Hospital Pricing: the Case of Colon Cancer Surgeries
Deb, Partha; Grossman, Michael; Dor, Avi; Cooper, Gregory; … - National Bureau of Economic Research (NBER) - 2013
We estimate price regressions for surgical procedures used to treat colon cancer, a leading cause of cancer mortality. Using a claims database for self-insured employers, we focus on transaction prices, rather than more commonly available billing data that do not reflect actual payments made....
Persistent link: https://www.econbiz.de/10010692215
Cover Image
Pricing and Welfare in Health Plan Choice
Levin, Jonathan; Bundorf, M. Kate; Mahoney, Neale - National Bureau of Economic Research (NBER) - 2008
Prices in government and employer-sponsored health insurance markets only partially reflect insurers' expected costs of coverage for different enrollees. This can create inefficient distortions when consumers self-select into plans. We develop a simple model to study this problem and estimate it...
Persistent link: https://www.econbiz.de/10005710694
Cover Image
The Welfare Consequences of Hospital Mergers
Town, Robert; Wholey, Douglas; Feldman, Roger; Burns, … - National Bureau of Economic Research (NBER) - 2006
In the 1990s the US hospital industry consolidated. This paper estimates the impact of the wave of hospital mergers on welfare focusing on the impact on consumer surplus for the under-65 population. For the purposes of quantifying the price impact of consolidations, hospitals are modeled as an...
Persistent link: https://www.econbiz.de/10005713981
Cover Image
The Effect of Medicare Part D on Pharmaceutical Prices and Utilization
Duggan, Mark; Morton, Fiona Scott - National Bureau of Economic Research (NBER) - 2008
On January 1, 2006, the federal government began providing insurance coverage for Medicare recipients' prescription drug expenditures through a new program known as Medicare Part D. Rather than setting pharmaceutical prices itself, the government contracted with private insurance plans to...
Persistent link: https://www.econbiz.de/10005774476
Cover Image
The Distortionary Effects of Government Procurement: Evidence from Medicaid Prescription Drug Purchasing
Duggan, Mark; Morton, Fiona Scott - National Bureau of Economic Research (NBER) - 2004
The federal-state Medicaid program insures 43 million people for virtually all of the prescription drugs approved by the FDA. To determine the price that it will pay for a drug treatment, the government uses the average price in the private sector for that same drug. Assuming that Medicaid...
Persistent link: https://www.econbiz.de/10005778002
Cover Image
Pricing and Reimbursement in U.S. Pharmaceutical Markets
Berndt, Ernst R.; Newhouse, Joseph P. - National Bureau of Economic Research (NBER) - 2010
In this survey chapter on pricing and reimbursement in U.S. pharmaceutical markets, we first provide background information on important federal legislation, institutional details regarding distribution channel logistics, definitions of alternative price measures, related historical...
Persistent link: https://www.econbiz.de/10008531891
Cover Image
Bundling Among Rivals: A Case of Pharmaceutical Cocktails
Nicholson, Sean; Lucarelli, Claudio; Song, Minjae - National Bureau of Economic Research (NBER) - 2010
We empirically analyze the welfare effects of cross-firm bundling in the pharmaceutical industry. Physicians often treat patients with "cocktail" regimens that combine two or more drugs. Firms cannot price discriminate because each drug is produced by a different firm and a physician creates the...
Persistent link: https://www.econbiz.de/10008533391